Akari Therapeutics ADR (AKTX)

$13.51 +0.35 (2.66%)
Market Cap 16.27M
Revenue (ttm) 0.00
Net Income (ttm) -17.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 48,574
Avg Vol 975,480
Day's Range N/A - N/A
Shares Out 1.15M
Stochastic %K 63%
Beta 1.38
Analysts Sell
Price Target $27.00

Company Profile

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon,...

Industry: Biotechnology
Sector: Healthcare
Phone: 929 274 7510
Fax: 929 274 7553
Address:
401 East Jackson Street, Suite 3300, Tampa, United States
LanceSteinfield
LanceSteinfield Jul. 9 at 5:01 PM
Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $PMN $AIOS $KZIA $AKTX soon
1 · Reply
lecorb
lecorb Jul. 7 at 11:57 PM
$AKTX $CLRO $SKIN $SKYQ $TDTH Normal!👏🏼👊🏻
1 · Reply
topstockalerts
topstockalerts Jul. 7 at 11:55 PM
$AKTX buyers seem to be in no rush to let this go.
0 · Reply
Frederick879
Frederick879 Jul. 7 at 9:13 PM
Massive run starting on $VEEE ! Let's see a massive short squeeze on VEEE next! $AKTX $SKYQ $CLRO $FCEL Let's go VEEE 🚀
0 · Reply
NarutoBreakouts
NarutoBreakouts Jul. 7 at 8:44 PM
$AKTX $FATE $RGNX $JSPR Ther
0 · Reply
topstockalerts
topstockalerts Jul. 7 at 8:24 PM
Top Gainers PT2 $SKYQ $AKTX $TDTH $VRXA $BATL
0 · Reply
LFG2030
LFG2030 Jul. 7 at 8:12 PM
$SKIN MOON!!!!! FDA news $BATL $CLRO $TVRD $AKTX
0 · Reply
TheLocoPro
TheLocoPro Jul. 7 at 7:57 PM
$IMRN biotechs catching bids recently. This will see $5 soon enough. Moves on thin air! $SKIN $AKTX $BJDX biotech season coming 💥
1 · Reply
Frederick879
Frederick879 Jul. 7 at 7:32 PM
Massive run starting on $VEEE ! Let's see a massive short squeeze on VEEE next! $AKTX $SKYQ $EDHL $FCEL Let's go VEEE
1 · Reply
lecorb
lecorb Jul. 7 at 7:23 PM
$CLRO $SKIN $AKTX $SKYQ $TDTH
0 · Reply
Latest News on AKTX
Akari Therapeutics, Registration statement: Registration filing

Jul 8, 2026, 8:00 AM EDT - 2 days ago

Akari Therapeutics, Registration statement: Registration filing

Akari Therapeutics (AKTX) Stock Rallies on a Scientific Advisory Board Addition

2026-07-07T17:34:13.000Z - 3 days ago

Akari Therapeutics (AKTX) Stock Rallies on a Scientific Advisory Board Addition

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Jul 7, 2026, 8:55 AM EDT - 3 days ago

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Akari Therapeutics, Registration statement: Registration filing

Jul 2, 2026, 8:00 AM EDT - 8 days ago

Akari Therapeutics, Registration statement: Registration filing

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Jun 29, 2026, 8:45 AM EDT - 11 days ago

Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones

Akari Therapeutics, Registration statement: Registration filing

Jun 26, 2026, 8:00 AM EDT - 14 days ago

Akari Therapeutics, Registration statement: Registration filing

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026

Jun 4, 2026, 9:30 AM EDT - 5 weeks ago

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026

Akari Therapeutics, Proxy statement: Proxy filing

Jun 4, 2026, 8:00 AM EDT - 5 weeks ago

Akari Therapeutics, Proxy statement: Proxy filing

Akari Therapeutics trading resumes

2026-05-28T17:06:49.000Z - 6 weeks ago

Akari Therapeutics trading resumes

Akari Therapeutics trading halted, volatility trading pause

2026-05-28T13:56:00.000Z - 6 weeks ago

Akari Therapeutics trading halted, volatility trading pause

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

May 28, 2026, 9:17 AM EDT - 6 weeks ago

Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance

Akari Therapeutics trading halted, volatility trading pause

2026-05-26T16:51:25.000Z - 6 weeks ago

Akari Therapeutics trading halted, volatility trading pause

Akari Therapeutics trading resumes

2026-05-26T16:45:36.000Z - 6 weeks ago

Akari Therapeutics trading resumes

3 Penny Stocks to Watch Now, 5/26/26

2026-05-26T14:40:48.000Z - 6 weeks ago

3 Penny Stocks to Watch Now, 5/26/26

LFS QTEX

Akari Therapeutics Stock (AKTX) Explodes 242% on Strong Cancer Drug Data and $5.5M Funding Boost

2026-05-22T19:38:16.000Z - 6 weeks ago

Akari Therapeutics Stock (AKTX) Explodes 242% on Strong Cancer Drug Data and $5.5M Funding Boost

Akari Therapeutics trading resumes

2026-05-22T17:50:10.000Z - 7 weeks ago

Akari Therapeutics trading resumes

Akari Therapeutics trading halted, volatility trading pause

2026-05-22T17:45:57.000Z - 7 weeks ago

Akari Therapeutics trading halted, volatility trading pause

Akari Therapeutics, Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 7 weeks ago

Akari Therapeutics, Proxy statement: Proxy filing

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

May 21, 2026, 5:01 PM EDT - 7 weeks ago

Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models

Akari Therapeutics Announces $5.5 Million Private Placement Offering

May 21, 2026, 8:30 AM EDT - 7 weeks ago

Akari Therapeutics Announces $5.5 Million Private Placement Offering

Akari Therapeutics, Quarterly report: Q1 2026

May 19, 2026, 7:00 AM EDT - 7 weeks ago

Akari Therapeutics, Quarterly report: Q1 2026

Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase

May 18, 2026, 9:05 AM EDT - 7 weeks ago

Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase

Akari Therapeutics secures European patent for Thailanstatin-based payloads

2026-05-12T13:57:28.000Z - 2 months ago

Akari Therapeutics secures European patent for Thailanstatin-based payloads

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

May 12, 2026, 8:33 AM EDT - 2 months ago

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Akari Therapeutics, Registration statement: Registration filing

May 8, 2026, 8:00 AM EDT - 2 months ago

Akari Therapeutics, Registration statement: Registration filing

Akari Therapeutics receives Australian patent for core payload technology

2026-04-27T13:27:26.000Z - 2 months ago

Akari Therapeutics receives Australian patent for core payload technology

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Apr 27, 2026, 8:35 AM EDT - 2 months ago

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Apr 21, 2026, 9:00 AM EDT - 2 months ago

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Akari Therapeutics announces presentation of preclinical data for AKTX-101

2026-04-20T14:32:23.000Z - 2 months ago

Akari Therapeutics announces presentation of preclinical data for AKTX-101

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Apr 20, 2026, 8:35 AM EDT - 2 months ago

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Akari Therapeutics downgraded to Hold from Buy at Maxim

2026-04-09T13:05:47.000Z - 3 months ago

Akari Therapeutics downgraded to Hold from Buy at Maxim

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

Apr 9, 2026, 8:50 AM EDT - 3 months ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

Akari Therapeutics downgraded to Hold from Buy at Maxim

2026-04-08T12:08:04.000Z - 3 months ago

Akari Therapeutics downgraded to Hold from Buy at Maxim

Akari Therapeutics announces strategic partnership with WuXi XDC

2026-04-06T13:20:35.000Z - 3 months ago

Akari Therapeutics announces strategic partnership with WuXi XDC

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

Apr 6, 2026, 8:45 AM EDT - 3 months ago

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

Akari Therapeutics target adjusted to $27 from $1.60 at H.C. Wainwright

2026-04-01T10:13:11.000Z - 3 months ago

Akari Therapeutics target adjusted to $27 from $1.60 at H.C. Wainwright

Akari Therapeutics trading halted, news pending

2026-03-30T23:51:11.000Z - 3 months ago

Akari Therapeutics trading halted, news pending

Akari Therapeutics, Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Akari Therapeutics, Annual report: Q4 2025

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Mar 18, 2026, 8:05 AM EDT - 4 months ago

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Akari Therapeutics Announces ADS Ratio Change

Mar 17, 2026, 4:30 PM EDT - 4 months ago

Akari Therapeutics Announces ADS Ratio Change

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Mar 13, 2026, 9:15 AM EDT - 4 months ago

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

Feb 26, 2026, 9:10 AM EST - 4 months ago

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Feb 18, 2026, 9:05 AM EST - 5 months ago

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

Akari Therapeutics, Slides: Corporate presentation

Feb 12, 2026, 7:00 AM EST - 5 months ago

Akari Therapeutics, Slides: Corporate presentation

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

Feb 11, 2026, 8:45 AM EST - 5 months ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline

Akari Therapeutics, Transcript: Study update

Feb 10, 2026, 7:00 PM EST - 5 months ago

Akari Therapeutics, Transcript: Study update

Akari Therapeutics, Press release: Study update

Feb 10, 2026, 7:00 PM EST - 5 months ago

Akari Therapeutics, Press release: Study update

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 5 months ago

Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Akari Therapeutics, Proxy statement: Proxy Filing

Feb 2, 2026, 7:00 AM EST - 5 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Jan 26, 2026, 8:45 AM EST - 5 months ago

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Akari Therapeutics, Registration statement: Registration Filing

Jan 23, 2026, 7:00 AM EST - 6 months ago

Akari Therapeutics, Registration statement: Registration Filing

Akari Therapeutics, Proxy statement: Proxy Filing

Jan 22, 2026, 7:00 AM EST - 6 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Jan 9, 2026, 9:00 AM EST - 6 months ago

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Akari Therapeutics to Present at the 2026 Biotech Showcase

Jan 8, 2026, 9:15 AM EST - 6 months ago

Akari Therapeutics to Present at the 2026 Biotech Showcase

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Dec 30, 2025, 9:15 AM EST - 6 months ago

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Dec 23, 2025, 8:30 AM EST - 7 months ago

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Dec 18, 2025, 8:30 AM EST - 7 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

Dec 16, 2025, 9:29 AM EST - 7 months ago

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

Dec 9, 2025, 8:40 AM EST - 7 months ago

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment

Dec 4, 2025, 9:00 AM EST - 7 months ago

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Nov 25, 2025, 9:00 AM EST - 8 months ago

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Nov 18, 2025, 8:35 AM EST - 8 months ago

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Akari Therapeutics, Registration statement: Registration Filing

Nov 17, 2025, 7:00 AM EST - 8 months ago

Akari Therapeutics, Registration statement: Registration Filing

Akari Therapeutics, Proxy statement: Proxy Filing

Nov 17, 2025, 7:00 AM EST - 8 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Akari Therapeutics, Earnings release: Q3 2025

Nov 13, 2025, 12:00 AM EST - 8 months ago

Akari Therapeutics, Earnings release: Q3 2025

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Nov 10, 2025, 8:30 AM EST - 8 months ago

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Akari Therapeutics, Proxy statement: Proxy Filing

Nov 7, 2025, 7:00 AM EST - 8 months ago

Akari Therapeutics, Proxy statement: Proxy Filing

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Nov 4, 2025, 9:25 AM EST - 8 months ago

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Oct 30, 2025, 8:35 AM EDT - 9 months ago

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 22, 2025, 9:05 AM EDT - 9 months ago

Akari Therapeutics Announces Launch of CEO Corner Platform

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Oct 15, 2025, 8:30 AM EDT - 9 months ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Oct 9, 2025, 8:45 AM EDT - 9 months ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Oct 3, 2025, 9:30 AM EDT - 10 months ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Sep 24, 2025, 8:45 AM EDT - 10 months ago

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Sep 17, 2025, 8:45 AM EDT - 10 months ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 6:45 AM EDT - 11 months ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Sep 3, 2025, 8:30 AM EDT - 11 months ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Akari Therapeutics, Registration statement: Registration Filing

Aug 29, 2025, 8:00 AM EDT - 11 months ago

Akari Therapeutics, Registration statement: Registration Filing

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 11 months ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Akari Therapeutics, Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Akari Therapeutics, Quarterly report: Q2 2025

Akari Therapeutics, Registration statement: Registration Filing

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Registration statement: Registration Filing

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 23, 2025, 8:55 AM EDT - 1 year ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 1 year ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 25, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Jun 18, 2025, 8:50 AM EDT - 1 year ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Akari Therapeutics, Slides: Company Presentation

Jun 13, 2025, 5:14 PM EDT - 1 year ago

Akari Therapeutics, Slides: Company Presentation

Akari Therapeutics, Proxy statement: Proxy Filing

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Proxy statement: Proxy Filing

Akari Therapeutics, Transcript: Webull Corporate Connect: Virtual Biotech Investment Webinar

May 29, 2025, 2:20 PM EDT - 1 year ago

Akari Therapeutics, Transcript: Webull Corporate Connect: Virtual Biotech Investment Webinar

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 29, 2025, 9:15 AM EDT - 1 year ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Akari Therapeutics, Proxy statement: Proxy Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Akari Therapeutics, Proxy statement: Proxy Filing

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 9:00 AM EDT - 1 year ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

LanceSteinfield
LanceSteinfield Jul. 9 at 5:01 PM
Banked from @TopSarge alerts the last few weeks, timing’s been on point! Follow him so you don't miss out 🔥 $PMN $AIOS $KZIA $AKTX soon
1 · Reply
lecorb
lecorb Jul. 7 at 11:57 PM
$AKTX $CLRO $SKIN $SKYQ $TDTH Normal!👏🏼👊🏻
1 · Reply
topstockalerts
topstockalerts Jul. 7 at 11:55 PM
$AKTX buyers seem to be in no rush to let this go.
0 · Reply
Frederick879
Frederick879 Jul. 7 at 9:13 PM
Massive run starting on $VEEE ! Let's see a massive short squeeze on VEEE next! $AKTX $SKYQ $CLRO $FCEL Let's go VEEE 🚀
0 · Reply
NarutoBreakouts
NarutoBreakouts Jul. 7 at 8:44 PM
$AKTX $FATE $RGNX $JSPR Ther
0 · Reply
topstockalerts
topstockalerts Jul. 7 at 8:24 PM
Top Gainers PT2 $SKYQ $AKTX $TDTH $VRXA $BATL
0 · Reply
LFG2030
LFG2030 Jul. 7 at 8:12 PM
$SKIN MOON!!!!! FDA news $BATL $CLRO $TVRD $AKTX
0 · Reply
TheLocoPro
TheLocoPro Jul. 7 at 7:57 PM
$IMRN biotechs catching bids recently. This will see $5 soon enough. Moves on thin air! $SKIN $AKTX $BJDX biotech season coming 💥
1 · Reply
Frederick879
Frederick879 Jul. 7 at 7:32 PM
Massive run starting on $VEEE ! Let's see a massive short squeeze on VEEE next! $AKTX $SKYQ $EDHL $FCEL Let's go VEEE
1 · Reply
lecorb
lecorb Jul. 7 at 7:23 PM
$CLRO $SKIN $AKTX $SKYQ $TDTH
0 · Reply
topstockalerts
topstockalerts Jul. 7 at 7:18 PM
Top Gainers $$CLRO $CRNX $TVRD $AKTX
0 · Reply
Flippinn_Stockz
Flippinn_Stockz Jul. 7 at 6:36 PM
$AKTX $BIAF $CLRO $SKIN $TVRD BIAF… huge run coming 👀💎😈✅
0 · Reply
Flippinn_Stockz
Flippinn_Stockz Jul. 7 at 6:27 PM
$BIAF i can’t believe the narket missed this one! Key wordss LOW FLOATER BOTTOM. Looking for a $SKIN move or $CLRO $AKTX $TVRD
0 · Reply
topstockalerts
topstockalerts Jul. 7 at 5:37 PM
Top Gainers PT2 $TDTH $TVRD $AKTX $BJDX $SKYQ
0 · Reply
dan16
dan16 Jul. 7 at 5:19 PM
$AKTX this is very positive IMO. A quick google search says Lorusso is a nationally recognized expert in developing new cancer drugs through clinical trials. A lot out there.
0 · Reply
Bossbaby14
Bossbaby14 Jul. 7 at 4:31 PM
$AKTX $TVRD looking like she’s trying to reclaim vwap
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 7 at 4:19 PM
Thin Watchlist- Moving Higher $PHOE $SOBR $AKTX $VS $XHLD
0 · Reply
akaritx
akaritx Jul. 7 at 1:27 PM
$AKTX Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-appoints-former-aacr-president-and-renowned
0 · Reply
focafoca99
focafoca99 Jul. 2 at 10:17 PM
$AKTX disclosed its annual general meeting results, re-electing directors and appointing new audit committee member.
0 · Reply
MTN
MTN Jun. 29 at 5:06 PM
$AKTX surprise, surprise. More raises at insider prices. I wonder if insiders are the ones shorting this to oblivion as they continuously spend down investor funds every year. This raise is nothing but dilution and more empty promises that will result in nothing. No partnership in sight, which means this is effectively not worth investing in for the foreseeable future.
0 · Reply
akaritx
akaritx Jun. 29 at 1:12 PM
$AKTX Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-completes-previously-announced-pipe
0 · Reply
focafoca99
focafoca99 Jun. 29 at 1:05 PM
$AKTX bolstered its balance sheet with $8.3M PIPE completion.
0 · Reply